4844 related articles for article (PubMed ID: 3070530)
21. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
[TBL] [Abstract][Full Text] [Related]
22. Immunological effects of adoptive immunotherapy with IL-2: an overview.
Kradin R; Yamin R; Kurnick J
Pathol Immunopathol Res; 1988; 7(6):434-41. PubMed ID: 3070529
[No Abstract] [Full Text] [Related]
23. Current approaches to the adoptive immunotherapy of cancer.
Yang JC; Rosenberg SA
Adv Exp Med Biol; 1988; 233():459-67. PubMed ID: 3265581
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
25. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
Taguchi T; Domoto K
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
[TBL] [Abstract][Full Text] [Related]
26. The role of interleukin-2 in cancer immunotherapy.
Eberlein TJ; Schoof DD
Compr Ther; 1991 Jan; 17(1):49-56. PubMed ID: 2001612
[TBL] [Abstract][Full Text] [Related]
27. Activation of T lymphocytes for the adoptive immunotherapy of cancer.
Sussman JJ; Shu S; Sondak VK; Chang AE
Ann Surg Oncol; 1994 Jul; 1(4):296-306. PubMed ID: 7850528
[TBL] [Abstract][Full Text] [Related]
28. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
29. [A study to increase the therapeutic effects of adoptive immunotherapy in vivo. Influence on the generation of lymphokine activated killer (LAK) cells and therapeutic effects of LAK cells with anti-tumor drug (cyclophosphamide)].
Yoshimori K
Nihon Ika Daigaku Zasshi; 1992 Oct; 59(5):418-27. PubMed ID: 1430114
[TBL] [Abstract][Full Text] [Related]
30. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.
Ochoa AC; Gromo G; Alter BJ; Sondel PM; Bach FH
J Immunol; 1987 Apr; 138(8):2728-33. PubMed ID: 2435804
[TBL] [Abstract][Full Text] [Related]
31. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
32. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
Takai N; Tanaka R; Yoshida S; Hara N; Saito T
Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
[TBL] [Abstract][Full Text] [Related]
33. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.
Lotze MT; Rosenberg SA
Immunobiology; 1986 Sep; 172(3-5):420-37. PubMed ID: 3100435
[TBL] [Abstract][Full Text] [Related]
34. Adoptive transfer of H-2-incompatible lymphokine-activated killer (LAK) cells: an approach for successful cancer immunotherapy free from graft-versus-host disease (GVHD) using murine models.
Toshitani A; Taniguchi K; Himeno K; Kawano Y; Nomoto K
Cell Immunol; 1988 Sep; 115(2):373-82. PubMed ID: 3409329
[TBL] [Abstract][Full Text] [Related]
35. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
36. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells.
Richards JM
Blood Rev; 1989 Jun; 3(2):110-9. PubMed ID: 2673443
[TBL] [Abstract][Full Text] [Related]
38. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
39. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
Law TM; Motzer RJ; Mazumdar M; Sell KW; Walther PJ; O'Connell M; Khan A; Vlamis V; Vogelzang NJ; Bajorin DF
Cancer; 1995 Sep; 76(5):824-32. PubMed ID: 8625186
[TBL] [Abstract][Full Text] [Related]
40. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.
Rodolfo M; Salvi C; Bassi C; Parmiani G
Cancer Immunol Immunother; 1990; 31(1):28-36. PubMed ID: 2306753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]